Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 37 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P50 CA192937
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: P01 CA190174
National Institutes of Health
Grant: 3P01CA190174-04S1
Immunologic Approaches to Ovarian Cancer
National Institutes of Health
Grant: 5P50CA192937-02
MSK SPORE in Lymphoma
FWCI
3.93
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
Additional file 1 of Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
Additional file 1 of Structural basis for antibody recognition of the proximal MUC16 ectodomain
Additional file 1 of Structural basis for antibody recognition of the proximal MUC16 ectodomain